Updates are available Correction dated 2022-10-13
Click to view Correction: https://doi.org/10.1038/s41431-022-01209-4
-
Authors
Wong, Kingsley
Junaid, Mohammed
Demarest, Scott
Saldaris, Jacinta
Benke, Tim A.
Marsh, Eric D.
Downs, Jenny
Leonard, Helen https://orcid.org/0000-0001-6405-5834
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1117105)
Department of Health | National Health and Medical Research Council (1117105)
- License Information
-
More Information
Article History
Received: 31 January 2022
Revised: 22 April 2022
Accepted: 21 July 2022
First Online: 18 August 2022
Change Date: 10 October 2022
Change Type: Update
Change Details: In the sentence beginning ‘Similarly...’ in the third paragraph in Discussion, “p.Arg559*” should have been “p.Arg550*”.
Change Date: 13 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41431-022-01209-4
COMPETING INTERESTS
: H.L. and J.D. have consulted for Avexis, Anavex, GW, Newron and Neurogene on unrelated subject matter. Both H.L. and J.D. have funding from the NIH related to this subject matter. H.L. and J.D. have consulted for Ovid Therapeutics and Marinus on related subject matter. T.B. has received funding from the NIH and the Children’s Hospital Foundation on related subject matter. He has consulted for Neuren/Acadia, Ovid/Takeda, AveXis, Marinus Taysha, Alcyone, and Marinus. All compensation has been made to his department. S.D. has funding from the NIH and International foundation for CDKL5 research related to this subject matter. He has consulted for Marinus and Ovid Therapeutics on related subject matter. He is a Scientific Advisory Board Member for Families SCN2A and SLC6A1 Connect. E.D.M has funding from the NIH, Orphan Disease Center at the University of Pennsylvania, International foundation for CDKL5 research, and LouLou Foundation related to this subject matter. He has funding from the NIH, Orphan Disease Center, Eagles Autism Foundation, for work not related. He is a site PI for industry sponsored trials for Marinus Pharmaceuticals, Zogenix Pharmaceuticals, Stoke Therapeutics, Epygenix Pharmaceuticals, and Takeda Pharmaceuticals on related subject matter. He is a Scientific Advisory Board Member for International Rett Syndrome Foundation and Lennox Gastaut Foundation. The remaining authors have no competing interests.
: The Human Research Ethics Committee, University of Western Australia provided approval for this study.
